Moderna omicron booster

Moderna Timeline

By Elmalisy
  • Foundation

    Foundation

    Moderna is founded by Noubar Afeyan, Derrick Rossi, Robert Langer, and Kenneth Chien.
  • $40 million funding

    $40 million funding

    Moderna raises $40 million in Series A funding.
  • Create a personalized cancer vaccine in mice

    Create a personalized cancer vaccine in mice

    Moderna announces it has successfully used its mRNA technology to create a personalized cancer vaccine in mice.
  • AstraZeneca Partnership

    AstraZeneca Partnership

    Moderna partners with AstraZeneca to develop mRNA-based therapies for cardiovascular, metabolic, and renal diseases as well as cancer.
  • Company valuing $5 billion

    Company valuing $5 billion

    Moderna raises $474 million in a Series F funding round, valuing the company at $5 billion.
  • Moderna's mRNA-1647 vaccine for cytomegalovirus enters Phase 1 clinical trials

    Moderna's mRNA-1647 vaccine for cytomegalovirus enters Phase 1 clinical trials

    Moderna's mRNA-1647 vaccine for cytomegalovirus enters Phase 1 clinical trials
  • The largest biotech IPO in history

    The largest biotech IPO in history

    Moderna becomes the largest biotech IPO in history, raising $604 million in its initial public offering.
  • Clinical trials for for human metapneumovirus

    Clinical trials for for human metapneumovirus

    Moderna's mRNA-1653 vaccine for human enters Phase 1 clinical trials.
  • COVID-19 Clinical Trials

    COVID-19 Clinical Trials

    Moderna's COVID-19 vaccine enters clinical trials and is shown to be highly effective in preventing COVID-19.
  • FDA approval for Emergency Use

    FDA approval for Emergency Use

    Moderna's COVID-19 vaccine is granted Emergency Use Authorization by the FDA.
  • Positive results in adolescents Phase 2/3 trial

    Positive results in adolescents Phase 2/3 trial

    Moderna announces positive results from a Phase 2/3 trial of its COVID-19 vaccine in adolescents.
  • Moderna seasonal flu vaccine

    Moderna seasonal flu vaccine

    Moderna announces it is developing a vaccine for the seasonal flu using mRNA technology.
  • FDA approval for COVID-19 vaccine

    FDA approval for COVID-19 vaccine

    Moderna receives FDA approval for its COVID-19 vaccine.
  • Rare Genetic Diseases clinical trials

    Rare Genetic Diseases clinical trials

    Moderna's mRNA-based therapies for rare genetic diseases enter clinical trials.